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ABSTRACT
Introduction. Published literature on type 1 diabetes 
(T1DM) patients from India suggests that a substantial 
number of them are negative to GAD 65 and IA-2 an-
tibodies. Antibody positivity rates have been linked to 
dietary and socio-economic factors and more recently, 
to changes in the enterobiome. Our anecdotal evidence 
indicated that antibody positivity rates among newly 
diagnosed T1DM children were rising. In this presen-
tation we have formally collated our data on these 
antibodies, a first, we believe, in the Indian pediatric 
population.
Material and methods. T1DM was diagnosed by stand-
ard clinical criteria advocated by American Diabetes 
Association including in all patients, the presence of 
diabetic ketoacidosis (DKA). We used plasma blood 
glucose rather than A1C to diagnose the acute onset 
of type 1 diabetes in individuals with symptoms of hy-
perglycemia. All patients with this diagnosis had GAD 
(glutamic acid decarboxylase) and IA-2 (insulinoma 
antigen 2) antibodies measured as a routine procedure 
from 2007. Data on patients between the ages of 1 and 
16 years as on 31st August 2016 were collected for this 
study. The antibodies were measured by standard RIA 
kits from the same manufacturer and performed in the 
endocrinology laboratory of one of the institutions.
Results. We included 694 T1DM cases from 2007 till 
2016, out of which 296 were antibody positive. A total 
of 172 were GAD antibody positive, 62 were IA-2 anti-
body positive and 90 exhibited dual antibody positivity 
(GAD positive + IA-2 positive). The chi-square test for 
trend analysis showed a significant rising trend for 
IA-2 antibody alone positive (p < 0.001, chi-square for 
trend = 17.437, df = 1) and either antibody positive 
percentages (p < 0.001, chi-square for trend = 22.71, 
df = 1), but not in the GAD antibody positivity (p = 
0.059, chi-square for trend = 3.567, df = 1) and in dual 
antibody positive percentages (p = 0.486, chi-square 
for trend = 0.485, df = 1) over a period of 9 years i.e. 
from 2007 to 2016.
Conclusion. Antibody positivity rates in recently di-
agnosed T1DM children have changed fairly rapidly 
over the last nine years. This surge in autoimmunity 
may also be a significant contributing factor towards 
the recent increased incidence of T1DM in India. (Clin 
Diabetol 2019; 8, 2: 116–120)
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Introduction
Type 1 diabetes mellitus (T1DM) is a disease caused 
by an autoimmune destruction of b-cells, and is clinical-
ly manifest when almost 90% of pancreatic islet b-cells 
are destroyed [1, 2]. It is a T-cell — mediated disease 
caused predominantly by CD4 positive cells. Islet cell 
antibodies (ICA), glutamic acid-decarboxylase (GAD65) 
antibodies, and insulin auto antibodies (IAA) are posi-
tive at diagnosis in over 85 % of Western T1DM patients 
[3–7]. The incidence of T1DM is growing at a rate of 
3–5% every year [8, 9]. Of the world wide estimate of 
490,000 children with T1DM, 24% are in the European 
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region and 23% in the South East Asian region [10]. 
There are an estimated prevalence of 97,700 children 
with T1DM in India with an annual incidence of 3 new 
patients with T1DM per 100,000 children over a period 
of 13 years from 1995 to 2008 in the age group 0–16 
years. Patients from India account for most of the pedi-
atric prevalence of T1DM in South East Asia [11]. It has 
been hypothesized that environmental and microbial 
factors play a role in the rising incidence of T1DM [12]. 
Alterations in the composition of the enterobiome have 
been experimentally linked with the development of 
T1DM. In Non-Obese Diabetic (NOD) mice, a standard 
model of T1DM, the males have a lower incidence of 
T1DM than females. If the enterobiome of the male is 
altered to the female pattern, the incidence of T1DM 
rises to the female rate [13–16].
Historically, more than 40% of T1DM patients 
in India were antibody negative [17]. There are no 
significant studies from India tracing the change in 
auto-antibody positivity in recently diagnosed T1DM. 
We wanted to determine whether the antibody posi-
tivity of newly diagnosed T1DM children patients have 
changed since 2007, i.e. since the time we have been 
performing antibody measurements.
Materials and methods
The current study was a retrospective study, per-
formed in two secondary referral endocrine clinics. The 
protocol was presented to the Ethics Committees of the 
two centers who felt that given the retrospective chart 
review nature of the study, informed consent is not 
neccesary We used plasma blood glucose rather than 
A1C to diagnose the acute onset of type 1 diabetes in 
individuals with symptoms of hyperglycemia. Patients 
with DKA and typical clinical features of T1DM as per 
the American Diabetes Association (ADA) position 
statement of 2017 and aged 1–16 years were included 
in the study [18]. In this retrospective chart review, we 
have only included patients with a confirmed diagno-
sis of type 1 diabetes, diagnosed by standard clinical 
criteria advocated by American Diabetes Association. 
All our patients had confirmed diagnosis of diabetic 
ketoacidosis (DKA) along with ketonuria. This finding 
strengthened the clinical diagnosis of T1DM in our pa-
tients and ensured that young type 2 diabetes patients 
were excluded.
Patients with pancreatitis, any feature suggestive 
of type 2 diabetes (T2DM), and diabetes from second-
ary causes were excluded from the study. Neonatal 
diabetes was excluded by age as the lower age limit 
for inclusion in the study is one year. Patient records 
meeting the eligibility criteria were evaluated from 
January 2007 to 31st August 2016. Blood samples were 
collected for estimation of glucose, C-peptide, GAD 
and IA-2 autoantibody in all patients. Venous blood 
sampling was done once the acute metabolic crisis 
was over and before oral feeding was allowed, in one 
center and after discharge in the other center. Lipemic 
or grossly haemolysed samples were discarded and 
the test repeated. The kits used came from the same 
manufacturer all through and the tests were done in 
one center. Antibodies to glutamic acid decarboxylase 
(GAD) and insulinoma antigen-2 were measured in all 
newly diagnosed T1DM patients’ (n = 692). Serum 
C-peptide values were required to be below the refer-
ence range. The samples were centrifuged at 2000 r.p.m. 
(at room temperature) for 15 min to separate the plas-
ma. Plasma was decomplemented by heating at 56°C 
for 30 min and stored in aliquots at –20° C with 0.1% 
sodium azide as preservative. Serum GAD-Ab and IA-2 
Ab titers were measured by I125 RIA technique (DLD DI-
AGNOSTIKA, GmBH, GERMANY) and C-peptide was es-
timated by RIA (IMMUNOTECH, FRANCE) [19]. For GAD 
and IA-2 antibody a titer ≤ 1.0 U/ml was considered 
normal while for C-peptide a fasting value ≥ 1.1 ng/ml 
was considered normal. Precision within the assay series 
was evaluated by processing 10 serum replicates. For 
GAD-Ab, IA-2Ab and C-peptide the results were mean 
5.1 ± 0.96 U/ml (%CV 3.9), mean 3.6 ± 0.85 U/ml (%CV 
2.7) and mean 1.05 ± 0.14 ng/ml (% CV 0.8) respec-
tively. The assay sensitivities for GAD-Ab, IA-2Ab and 
C-peptide were 0.21 U/ml, 0.19 U/ml and 0.036 ng/ml 
respectively, as obtained from kit literature. It may be 
noted that the ADA does not advise measurement of 
C-peptide, thyroid function tests or screening for celiac 
disease during the initial metabolic crisis [20, 21]. This is 
because C-peptide values can be excessively depressed 
at this time, while thyroid function tests can be vitiated 
due to sick euthyroid syndrome and celiac screening 
affected by the lack of usual oral intake of gluten.
Statistical methods
Descriptive statistical analysis were carried out 
with SAS (Statistical Analysis System) version 9.2 for 
windows, SAS Institute Inc. Cary, NC, USA and Statisti-
cal Package for Social Sciences (SPSS Complex Samples) 
Version 21.0 for windows, SPSS, Inc., Chicago, IL, USA, 
with Microsoft Word and Excel being used to generate 
graphs and tables. Results on categorical measurements 
are presented in Number (%). Significance is assessed 
at a level of 5%.
Results
Auto-antibody positivity to b-cell antigens over 
a period of ten years i.e. from 2007 to 2016 is shown 
in Table 1. We included 694 T1DM cases from 2007 
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till 2016, out of which 296 were antibody positive. 
A total of 172 were GAD antibody positive, 62 were 
IA-2 antibody positive and 90 exhibited dual antibody 
positivity. The chi-square test for trend analysis showed 
a significant rising trend for IA-2 antibody alone posi-
tive (p < 0.001, chi-square for trend = 17.437, df = 1) 
and either antibody positive percentages (p < 0.001, 
chi-square for trend = 22.71, df = 1), but not in dual 
antibody positive percentages (p = 0.486, chi-square 
for trend = 0.485, df = 1) and in GAD antibody positiv-
ity (p = 0.059, chi-square for trend = 3.567, df = 1), 
though the p value for GAD antibody positivity fell in 
the range of suggestive significance. 
Discussion
For reasons unknown, low rates of antibody posi-
tivity are found in T1DM patients in Asia in comparison 
to their Western counterparts [4]. Prevalence of 26 to 
61% of antibody positivity in T1DM patients has been 
reported from North India [3, 5]. Tandon et al. have 
reported a 26% prevalence of GAD and/or IA-2Ab in 
T1DM patient with disease duration greater than 5 
years in north India. They found a 14% GAD positiv-
ity and 15% IA-2Ab positivity [4]. Some other studies 
[4] have reported higher rates of antibody positivity. 
Overall, variable antibody positivity rates have been 
reported from India, but were substantially lower 
than the 85–95% GAD positivity reported in Western 
populations [15–17].
Our study traced the autoantibody positivity of 
recently diagnosed T1DM patients over ten years in an 
East Indian pediatric population and found a secular 
trend of increased prevalence of antibody positivity 
(Table 1). Similar results were demonstrated by Ahmed 
et al. in 2008 where the authors found a prevalence 
of 47% of auto antibodies in their T1DM population. 
GAD65 antibody was positive in 41.2% and IA-2 in 
20.6%. A total of 14.7% TIDM subjects showed both 
GAD65 plus IA-2 autoantibody positivity [19]. 
There is a rising incidence of T1DM worldwide, and 
global estimates show significant increases of 4.0% in 
Asia, 3.2% in Europe and 5.3% in North America. The 
average annual increase in incidence of T1DM was 2.4% 
(95% CI 1.3–3.4%) during 1990–1994, and a higher 
increase of 3.4% (95% CI 2.7–4.3%) was recorded in the 
period 1995–1999. There is a suggestion in the Indian 
literature that the incidence of T1DM has been raising 
in the recent years [22]. Around 78,000 children under 
15 years of age are estimated to develop T1DM annually 
worldwide. An estimated 18,000 children under the 
age of 15 were newly diagnosed with T1DM in 2011 in 
India [23]. In south India, the Karnataka Type 1 Diabetes 
Registry reported an incidence of 3.7/100,000 in boys’ 
and 4.0/100,000 in girls, over 13 years of data collection 
[23]. Recently Kalra et al. reported a high prevalence 
(10.20/100,000 population) of T1DM in Karnal district 
in north India [24].
Wilkins had postulated an accelerator hypothesis 
where he linked weight gain with autoimmunity in 
T1DM in developed countries [25]. India being a fast 
developing country, has witnessed a rise in childhood 
obesity. Recently Jagadesan et al. had estimated 21.4% 
prevalence of childhood obesity among private school 
students in southern India [26]. Patterson and associ-
ates had further found a directly proportional relation-
ship between national prosperity and childhood onset 
T1DM, which fits the data from India [27]. The hygiene 
hypothesis proposed by Gale and McKinney et al. 
which goes hand in hand with Patterson’s hypothesis 
could also be one of the reasons for increases auto-
immunity in our study sample [28, 29]. This recent 
surge in autoimmunity of T1DM could be triggered by 
a change in the enterobiome of the population. A dec-
ade ago, in an Indian study of newly diagnosed T1DM, 
Table 1. Pattern of number of autoantibodies to b-cell antigen in the study sample
Year Total number  
of cases  
N = 694
GAD antibody  
positive 
N = 172
IA-2 antibody  
positive 
N = 62
Both antibodies 
positive 
N = 90
Both antibodies  
negative 
N = 371
Total positive  
cases 
N = 296
2007 29 6 (20.67) 1 (3.45) 4 (13.79) 18 (62.07) 11 (37.93)
2008 54 10 (18.52) 0 7 (12.96) 37 (68.52) 17 (31.48)
2009 70 12 (17.14) 4 (5.7) 7 (10) 47 (67.14) 23 (32.86)
2010 91 17 (18.68) 1 (1.09) 15 (16.48) 58 (63.74) 33 (36.26)
2011 97 38 (39.18) 2 (20.62) 11 (11.34) 46 (47042) 51 (52.57)
2012 64 14 (21.87) 9 (14.06) 6 (9.38) 35 (54.69) 29 (45.31)
2013–2014 203 53 (26.11) 31 (15.27) 19 (9.36) 101 (49.75) 102 (50.25)
2015–2016 86 22 (25.58) 14 (16.28) 21 (24.42) 29 (33.72) 57 (66.28)
GAD — glutamic acid decarboxylase; IA-2 — insulinoma antigen 2. Numbers in brackets denotes percentage
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Balasubramanium and colleagues demonstrated mono 
GAD antibody positivity of 42% and IA-2 positivity of 
33%. Considering the absence of GAD and IA-2 Ab’s 
in around 45% of the recently diagnosed Indian T1DM 
subjects, Bhatia postulated idiopathic (type 1B) patients 
to be substantially more frequent in the Indian popula-
tion as compared to the Caucasian [30].
Conclusion
Our study traces the autoantibody positivity of 
recently diagnosed T1DM children over past ten years 
in an East Indian population and found a significant 
increase of autoantibody positivity over time. As this 
was an observational retrospective study, we could not 
assign any definite cause to this increase in autoim-
munity. This surge in autoimmunity may be a signifi-
cant contributing factor towards the recent reported 
increased incidence of TIDM in India. 
Limitations
We have not included ZnT8 in our analysis since 
it is recently added in the panel of auto-antibodies 
for screening of T1DM from 2012 onwards. Since, we 
have included T1DM patients diagnosed from the year 
2007; we wanted to maintain uniformity of the tested 
antibody in the study. Hence the antibody ZnT8 was 
not tested.
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